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As the laws concerning the regulation of Cannabis Sativa change across the 
globe, maternal use of cannabinoid-containing products during pregnancy is a greater 
concern than ever before. Little research has been conducted on the consequences of 
maternal use and developmental exposure to ∆9-tetrahydrocannabinol (THC) and 
cannabidiol (CBD. In this study, larval zebrafish (Danio rerio) were used to measure 
CBD and THC-mediated adverse outcomes including effects on larval length, eye area, 
and behavior in the cnr+/+ and cnr2-/- zebrafish strains where we discovered that 
cannabinoid exposure results in a decrease in each of these endpoints. Adult zebrafish 
were used to further examine the effects that receptor knockout has on behavior which 
also resulted in decreased behavior. This study found that developmental exposure to 
THC and CBD did result in toxicities, however, toxicities were lessened in zebrafish that 
lacked cannabinoid receptor 2 suggesting that this receptor has an important role in 
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1.1 Cannabinoids as Therapeutics 
 
The most commonly used illicit drug in the United States, marijuana, is derived 
from the Cannabis sativa plant, but it is also known for its many medicinal indications 
(Ahmed et al., 2018). Cannabis sativa is a complex plant with over four hundred 
chemical components where more than sixty of these are cannabinoid compounds 
(Atakan 2012). Cannabinoids are lipophilic ligands that are found in all cannabis plant 
preparations with the best characterized being the psychoactive compound Δ9-
tetrahydrocannabinol (THC) and the non-psychotropic cannabidiol (CBD). Marijuana on 
the market currently typically has a THC composition from 12 – 30% on average while 
the range for CBD is from 1 – 20% (Royal Queen Seeds 2020).  
 
 
Figure 1: Structures of THC and CBD  
Made in ChemDoodle 11.3 
 2 
The actions of Cannabis sativa are considered to be primarily transduced by two 
transmembrane G-protein-coupled receptors known as cannabinoid receptor 1 (CB1R in 
humans, Cnr1 in fish) and cannabinoid receptor 2 (CB2R in humans, Cnr2 in fish) along 
with the subsequent secondary-messenger gene transcription changes. Although Cnr1 and 
Cnr2 are the most widely-acknowledged and characterized cannabinoid receptors, several 
other receptors from G-protein-coupled receptors to ion channels and nuclear receptors 
also interact with cannabinoids (Kano et al., 2009a). One important difference to note for 
this study revolves around the previously mentioned cannabinoid’s affinities for binding 
to Cnr1 and Cnr2. THC has a high affinity for Cnr1 and Cnr2 with low Ki values in the 
nanomolar range. CBD’s affinity, however, is much lower for both receptors, but it can 
interact with the cannabinoid receptors at low concentrations. CBD is also a weak Cnr1 
antagonist and Cnr2 inverse agonist (Maccarrone et al., 2015). In humans, CB1 and CB2 
proteins are encoded by the genes CB1 and CB2, respectively. However, throughout this 
paper, I will be using the zebrafish nomenclature Cnr1 and Cnr2 to represent the 
cannabinoid receptor proteins and cnr1 and cnr2 for the receptor genes.  
Cnr1 is encoded by the gene cnr1 and is the most prominent cannabinoid receptor 
subtype in the central nervous system, with the cnr1 receptor appearing first in the 
preoptic area at 24 hpf (Lam et al., 2006).  Cnr1 expression is highest in the olfactory 
bulb, hippocampus, basal ganglia, and cerebellum regions of the CNS (Mackie, 2005). As 
a result of this expression, Cnr1’s role in the endocannabinoid system revolves largely 
around regulating brain functions such as mood, anxiety, appetite, memory consolidation, 
and the control of locomotor activity (Gong et al., 2006). For example, Cnr1 modulates 
the mobility of the gastrointestinal tract and can control appetite from the hypothalamus 
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in the CNS and can regulate energy balance and metabolism through food intake from the 
gastrointestinal tract as well. Although it is predominately found in brain tissue, Cnr1 is 
also in adipose tissue, skeletal muscle, bone, skin, eye, and reproductive tissue 
(Maccarrone et al., 2015) . 
Cannabinoid receptor 2 was discovered in the macrophages of the human spleen 
three years after Cnr1 and is encoded by the gene cnr2 in zebrafish (Munro et al., 1993). 
cnr2 is predominately expressed in immune cells and was found have transcript levels 
that were over 10-fold higher than cnr1 transcript levels in leukocytes (Krug and Clark, 
2015). Along with its role in immunity, Cnr2 has moderate expression in other peripheral 
tissues including the cardiovascular system, GI tract, liver, adipose tissue, bone, and 
reproductive tissues (Gong et al., 2006). It was not, however, observed in a high extent in 
the brain when compared to its expression in immune cells or Cnr1’s presence in the 
brain (Atwood and MacKie, 2010). Although Cnr2’s expression in the central and 
peripheral nervous systems is limited, Cnr2 plays a less understood role in neurological 
activities such as nociception, drug addiction, and neuroinflammation (Pacher et al., 
2006). 
The endocannabinoid system is composed of the endogenous cannabinoid 
receptors such as Cnr1 and Cnr2, their endogenous lipid ligands, and the enzymes 
responsible for their biosynthesis and degradation. This system is widely distributed 
throughout the brain and body and is responsible for numerous significant regulatory 
functions in the neuronal, vascular, metabolic, immune, and reproductive systems 
(Pertwee et al., 2010). Most studies of the endocannabinoid system focus on the 
endogenous agonist N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-
 4 
AG) (Pertwee et al., 2010). AEA is a high-affinity partial agonist of Cnr1 and almost 
inactive at Cnr2 while 2-AG acts as a full agonist at both Cnr1 and Cnr2 with moderate to 
low affinity (di Marzo and de Petrocellis, 2012). Both endocannabinoids are produced on 
demand in response to increased intracellular Ca2+ concentration (Kano et al., 2009);; 
however, the basal level of 2-AG is approximately 1000 times higher than AEA in the 
brain, thus it is proposed that 2-AG is the primary endogenous ligand for cannabinoid 
receptors in the central nervous system (di Marzo and de Petrocellis, 2012). After it was 
discovered that the endocannabinoid system is involved in short and long-term 
depression at both excitatory and inhibitory synapses, the endocannabinoid system 
became the most studied retrograde signaling system in the brain (Ahmed et al., 2018). 
1.2 Cnr2 and Cnr2-KO 
cnr2 is located on chromosome 4 in mice and 1p36 in humans and is minimally 
divergent between species with sequence identity being 82% between human and mouse 
(Munro et al., 1993). When comparing the zebrafish genome to the human reference 
genome, approximately 70% of human genes have at least one obvious zebrafish 
orthologue (Howe 2013). Similar to Cnr1, Cnr2 is a member of the G-protein coupled 
receptor family of proteins and mediates its action via inhibition of adenylate cyclases 
(Ibsen et al., 2017). The receptor does this through initiation of signaling cascades such 
as the phospholipase C and inositol 1, 4, 5-triphosphate signaling pathways that both 
serve to increase the levels of intracellular calcium (Zoratti et al., 2003). Upon 
cannabinoid receptor interaction with its ligand, the G protein exchanges the inactive 
guanine in the GDP nucleotide for an active GTP form. The heterotrimeric G-protein 
dissociates into an α and βγ subunit where the α subunit inhibits adenylate cyclase 
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through binding which decreases second messenger cAMP levels downstream (Howlett 
and Mukhopadhyay, 2000). This decrease in cAMP production is a mode by which Cnr2 
signaling in response to endocannabinoids helps to maintain immunological homeostasis 
while in response to exogenous cannabinoids results in an immunosuppressive effect 
(Cabral et al., 2008).  
Exogenous cannabinoids decrease host resistance to a variety of infectious agents. 
This is because, as previously mentioned, Cnr2 is predominately distributed in cells and 
tissues of the immune system especially concentrated in the thymus, tonsils, B 
lymphocytes, T lymphocytes, macrophages, monocytes, and natural killer cells (Schatz et 
al., 1997). Cnr2 is expressed in highest amount in NK cells, macrophages, and T 
lymphocytes respectively (Núñez et al., 2004). Cnr2 is also expressed in the CNS during 
states of inflammation (Malfitano et al., 2014). It is for this reason that cannabinoids, as 
ligands through their receptors, are of interest for therapeutic treatment of 
hyperinflammatory immune responses in the CNS due to their anti-inflammatory actions 
(Cabral and Griffin-Thomas, 2009). For example, in mice, Δ9-THC synthetic 
cannabinoids CP55940 and HU-210 inhibit cell contact-dependent cytolysis of tumor 
cells that are mediated by macrophages (Burnette-Curley and Cabral, 1995; Coffey et al., 
1996) to suppress natural killer cells (Klein et al., 1991). Δ9-THC suppresses the 
development of B lymphocytes and T lymphocytes in response to mitogens (Burnette-
Curley and Cabral, 1995). These two examples show that exogenous cannabinoids inhibit 
the activity of a variety of immunocytes and that the immune actions of cannabinoids are 
functionally linked to Cnr2 to exert their effects on immune tissues (Galiegue et al., 
1995). 
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Although Cnr2 is primarily found in immune tissues, evidence suggests that Cnr2 
modulates other neuronal functions. For example, activation of Cnr2 reduces pain (Anand 
et al., 2009), impulsive behavior (Navarrete et al., 2012), and locomotor activity of 
rodents (Valenzano et al., 2005). Cnr2 polymorphism is also related to schizophrenia 
(Ishiguro et al., 2010), depression (Onaivi et al., 2008), and bipolar disorder (Minocci et 
al., 2011). Due to Cnr2’s apparent role in many neurological conditions, Cnr2 knockout 
studies have been particularly useful to further understand the role of Cnr2 in the body 
outside of immune tissues. For example, chronic activation of Cnr2 increases anxiety in 
rodents while chronic blockade decreases anxiety (García-Gutiérrez et al., 2013). Cnr2 
knockout mice also display a decline in long-term memory and hippocampus-dependent 
fear memory while hippocampus-independent fear memory was unaffected (Li and Kim, 
2016a). 
1.3 Cannabinoid Use as a Therapeutic Agent 
Plant-based cannabis and cannabinoid agents have been used both medicinally 
and recreationally since as early as 400 AD (Bridgeman and Abazia, 2017). As 
previously discussed, the endocannabinoid system is responsible for numerous significant 
regulatory functions, thus changes in endocannabinoid levels can lead to significant 
problems. Changes in endocannabinoid levels may be related to neurological diseases 
such as Parkinson's disease (Krishnan et al., 2009), Huntington's disease (Pazos et al., 
2008), and Alzheimer's disease (Shen and Thayer, 1998), as well as irritable bowel 
syndrome (Wong et al., 2012). 
Cannabinoid constituents are widely used to alleviate symptoms or treat disease, 
but their efficacy is not well established. Cannabinoid involvement in several 
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physiological processes, however, is well known. This regulatory role includes improving 
energy balance, appetite stimulation, blood pressure, pain modulation, embryogenesis, 
nausea and vomiting control, memory, learning and immune response as well as in 
pathological conditions where it exerts a protective role in the development of certain 
disorders (reviewed in: Fraguas-Sánchez et al., 2018).   
Because CBD is one of the cannabinoids with non-psychotropic action and 
antiseizure efficacy, it has been popularized for its use as a therapeutic to reduce epileptic 
seizures (Carty et al., 2019). Epilepsy affects more than fifty million people worldwide 
and can cause cognitive and sensorimotor deficits which greatly compromise the quality 
of life and increase the risk for premature death (Gloss and Vickrey, 2014; Sabaz et al., 
2003). Unfortunately, more than thirty percent of epileptic patients progress to drug-
resistant epilepsy which is defined as failure to achieve seizure freedom after trying two 
anti-epileptic drugs (AEDs) (Sheng et al., 2017) . In order to combat this issue, the Food 
and Drug Administration (FDA) and Drug Enforcement Agency (DEA) brought to 
market the first and only approved prescription cannabidiol called Epidiolex (Sheng et 
al., 2017). 
1.4 Effects of Developmental Cannabinoid Exposure 
 Our investigation is highly relevant in today’s society where over the last decade 
marijuana use by pregnant women has increased by approximately sixty-five percent in 
the United States particularly among those of low socioeconomic status. Metadata 
analysis indicates that marijuana use in pregnancy prior to or during pregnancy could 
contribute to dangerous pregnancy complications such as low fetal birth weight, preterm 
delivery, and congenital malformation and neonatal complications (Neradugomma et al., 
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2018). In a study done on nonusers and users during pregnancy, the mRNA levels of 
CNR1 and CNR2 were higher in the endometrium sample tissue taken from women who 
used marijuana during pregnancy than nonusers, and the CNR2 protein levels were 
higher in the endometrium as well. A successful reciprocal interaction is required 
between a competent embryo and receptive endometrium for a pregnancy to be 
successful, and marijuana use seems to compromise this by altering receptor expression 
in the endometrium (American College of Obstetricians and Gynecologists Committee on 
Obstetric Practice, 2015) . 
Receptors for cannabinoids can be detected in rodent animal models from the 
earliest stages of development (Schneider, 2009). In zebrafish, both receptors are 
expressed from as early as one hpf and into adulthood (Saint-Amant and Drapeau, 1998). 
These play an essential role in neuronal development; thus, it is increasingly important 
that the behavioral effects of cannabinoid administration both before and during 
pregnancy is understood. They do this by influencing the expression of neuron-glia cell 
adhesion molecules which shows cannabinoid’s influence on cell proliferation, neuronal 
migration, and axon elongation (Fernández-ruiz et al., 2004) . 
Understanding the effect of cannabinoid administration before and during 
pregnancy is crucial as CBD has been proven to be an anti-emetic due to its ability reduce 
vomiting in the Asian house shrew S. marinus; however, this mechanism was not 
mediated through CB1 or CB2 (Parker et al., 2004). Because of CBD’s ability to reduce 
vomiting, concerns have arisen over cannabinoid use as a treatment for nausea during 
pregnancy especially considering that cannabinoids are capable of freely crossing the 
placenta and may pose a significant risk to embryonic development (Neradugomma et al., 
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2018).  Previous zebrafish studies have shown a correlation between embryonic exposure 
to THC and irregular CNS development, but less is known about CBD’s impact on 
development (Richardson et al., 2017). 
1.5 Zebrafish as a Human Model for Disease 
 Although mammals have more commonly been used to model human diseases, 
the zebrafish (Danio rerio) is rapidly becoming a new popular model organism in 
biomedical research. The zebrafish model was chosen because it is a vertebrate species 
with high physiological and genetic homology to humans. Comparison of the zebrafish 
genome to the human reference genome shows that approximately 70% of human genes 
have at least one zebrafish homolog (Richardson et al., 2017). Meanwhile, 84% of known 
human disease-causing genes having a zebrafish counterpart (Ahmed et al., 2018). 
The zebrafish model allows for easy genetic manipulation because they have a 
similar central nervous system (CNS) morphology. Zebrafish embryos also offer a 
distinct advantage over mammalian models for toxicity and exposure studies as they 
develop externally in a chorion casing which is advantageous as researchers can visualize 
and study the different developmental stages starting from the earliest stages of 
embryogenesis. Along with this, researchers can dose during embryo development 
(Teame et al., 2019). Zebrafish are also advantageous due to their high fecundity, 
numerous strains, short generation time, and rapid embryonic development as they form 
complete organ systems within forty-eight hours of fertilization (Kalueff et al., 2014) .  
Some complex brain disorders that have been modeled by zebrafish are 
depression, autism, psychoses, drug abuse, and cognitive deficits (Souza Anselmo et al., 
2017). Zebrafish are also an appropriate model to use to study metabolic dysfunctions as 
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they contain all organs involved in energy homeostasis and metabolism including 
appetite and insulin regulation along with a lipid storage system all of which is conserved 
with that found in humans (Li and Kim, 2016b). 
1.6 Study Goals and Hypotheses 
We hypothesized that the cannabinoid receptors would play a significant mechanistic role 
in THC’s, but not CBD’s, acute toxic effects. The goals of our study were: 
1. Evaluate morphological differences such as mortality, larval eye area, and larval 
length between cnr+/+ and cnr2-/- zebrafish when exposed to CBD or THC.  
2. Evaluate the effect of cannabinoid receptors on larval behavior.  





II. MATERIALS AND METHODS 
 
2.1 Zebrafish Husbandry and Exposures 
Tg(fli1:egfp), 5D, cnr1-/- [Tu(cnr1zf679/zf679 )], cnr2-/- [Tu(cnr2zf680/zf680)] zebrafish 
strains were used in this study. All fish were raised and all experiments were conducted 
in accordance with the approved Institutional Animal Care and Use Committee (IACUC) 
guidelines and recommendations. Healthy adult fish were maintained in Aquatic Habitats 
Zebrafish Flow-through System (Aquatic Habitats, Apopka, Florida) under ambient 
conditions (pH 7.5–8.0, dissolved oxygen 7.2–7.8 mg/L, conductivity 730–770 mS, and 
temperature 27°C–29°C). Sexually mature and healthy fish without any signs of 
deformities or disease were selected as breeders.  
The Tg(fli1:egfp) strain was obtained through the Zebrafish International Resource 
Center (ZFIN, Eugene, OR) and represents cnr+/+  which was used as a wild type control. 
We have previously used this strain to assess the impact of developmental exposure to 
both CBD and THC (Carty et al. 2018; Carty et al. 2019; Pandelides, Thornton, Faruque, 
et al. 2020; Pandelides, Thornton, Lovitt, et al. 2020). Wild-type 5D zebrafish were 
kindly provided by Dr. Robyn Tanguay at Oregon State University and raised under the 
approved IACUC protocol (18-022). The cannabinoid receptor 1 and 2 mutant strains 
(cnr1+/+ and cnr2-/-) was provided by Dr. Wolfram Goessling (Genetics Division, 




This strain was genotyped prior to producing embryos used in experiments. For egg 
collection and larval exposures, embryos were obtained by transferring adult into tanks 
with a 1:1 ratio of males to females the night prior to collection. The next morning, eggs 
that fell through the protective grate at the bottom of the breeding tank were collected and 
debris were removed by pouring the water from the tanks through a sieve. The embryos 
were then randomly sorted into scintillation vials with ten embryos per vial and stored in 
the 28°C incubator. These vials contained embryo water with 1 embryo per 0.6 mL of 
embryo water (sterilized deionized water; pH of 7.4–7.7; 60 ppm Instant Ocean, 
Cincinnati, Ohio). These embryos were exposed under static conditions from 6 hours 
post-fertilization (hpf) - 96 hpf. Every 24h, embryos in the exposed vials were screened 
for any developmental defects, and debris such as mortality or sloughed chorions were 
removed. 
2.2 Determining the developmental toxicity to THC and CBD exposure in cnr 
mutants:  
Zebrafish embryos from the cnr+/+and cnr2-/- strains were exposed to 2, 4, 8, 9.5, 
and 12 μM (0.65, 1.25, 2.4, 3, 3.75 mg/L) THC or 0.25, 0.5, 1, 2, and 4 μM (0.075, 0.15, 
0.3, 0.6, 1.2 mg/L) CBD beginning at 6 hpf. A 0.05% DMSO (control) group was 
included as a carrier control. Exposures were continued under static conditions until 96 
hpf. Each treatment consisted of 5 biological replicates with 10 embryos per replicate.  
After behavioral assessments, photographs were taken of all surviving larval fish 
(50 larval fish per treatment, 10 per replicate, n =5 replicates) per treatment group to 
assess developmental deformities. Larvae were anesthetized in tricaine methanesulfonate 
(300 mg/L MS-222) buffered with 600 mg/L sodium bicarbonate. They were 
immediately placed on a microscope slide with a chamber containing 3% methyl 
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cellulose and a lateral image was captured with a MicroFire® camera (Optronics, Goleta, 
CA) attached to a Zeiss Stemi 2000-C Stereo Microscope (Jena, Germany) using Picture 
Frame™ Application 2.3 software (Optronics, Goleta, CA). The phenotypes were scored 
blindly using ImageJ software (Schneider et al., 2012). Total body length, diameter and 
area of the eye, presence or absence of developmental abnormalities (yolk sac edema, and 
pericardial edema) were recorded by three double-blinded reviewers.   
2.3 Larval Behavior Analysis 
Larval behavior was measured through the larval photomotor response test using 
a ViewPoint ZebraBox (ViewPoint, Montreal, Canada). This was done by transferring 
larvae into 96-well plates at the end of the exposure (96 hpf) where they were acclimated 
to the light and temperature of the room containing the ZebraBox for five minutes. The 
locomotor assay conditions were comprised of ten minutes under 100% light followed by 
ten minutes in the dark (0% light), and finishing with ten minutes back in the 100% light 
condition (Kirla et al. 2016).  The endpoints were measured over 2-minute intervals and 
the total distance traveled during the light and dark phases per larvae was measured and 
analyzed. Any larvae that were unable to swim due to malformations were excluded from 
behavioral analysis.  
2.4 Adult Behavior Analysis 
 To determine the role cannabinoid receptor 1 and 2 play in adult behavior, ten 
adult zebrafish that had been raised in clean conditions since 96 hpf were removed for 
each of the four strains being examined in this study (fli, 5D, cnr1-/-, and cnr2-/-).  These 
zebrafish were removed the morning of the behavioral analysis and each housing tank 
was separated into two tanks containing 5 males and 5 females in duplicate (10 males and 
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10 females per strain total). They were left to acclimate for approximately four hours in 
order to adjust to being in tanks with the same sex only. These tanks were then moved 
into a room with ambient lighting and temperature and were left to adjust for five 
minutes. Adult zebrafish were then removed one at a time and placed in an open field that 
is a well-established paradigm for assaying anxiety-related behaviors (Godwin et al 
2012). Their open field behavior was measured for six minutes and then the fish were 
removed and recombined into their original housing tanks. The analysis used was 




Figure 2: Two Zones of Behavior in the Open Field Test. For 
analysis, the swim arena was divided into two regions- 
periphery (outer 50% of the arena) and center (inner 50% of 
the arena). The diameter was 23 cm.  
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2.5 Statistical Analysis 
For mortality percentages, the percentage calculated for mortality was 
transformed into probit values and the dosage concentrations were plotted in log units. 
LC50s were calculated from a linear regression performed on the data points.  
All data were assessed for normality and homogeneity of variance using Shapiro-
Wilk and Brown-Forsythe tests, respectively. Larval length and eye area were recorded 
per fish and then averaged per replicate (n = 5). Differences in treatment within each 
strain were assessed by ANOVA, Dunnett’s posthoc, (p ≤ 0.05), in order to assess the 
difference between treated and the untreated control fish.  
Statistical analysis was conducted on the total distance travelled during the light 
and dark phases separately. Within each strain, differences in concentration were assed 
(ANOVA, Tukey’s posthoc, p ≤ 0.05). The differences in strain were assessed by 
performing pairwise comparisons between the two strains (ANOVA, Tukey’s posthoc, p 
≤ 0.05). If the data did not meet the assumptions of parametric tests, an ANOVA on 
Ranks was performed. All graphing and statistical analysis was conducted using 
Sigmaplot 14.0 software. 
Adult behavior was conducted on the total distance traveled and time spent in 
periphery. The differences in strain were assessed by performing pairwise comparisons 
between the two strains (ANOVA, Tukey’s posthoc, p ≤ 0.05). If the data did not meet 
the assumptions of parametric tests, an ANOVA on Ranks was performed. All graphing 






3.1 Role of Cnr2 in THC and CBD induced developmental toxicity 
When exposed to THC, there was a dose-dependent effect on mortality in both the 
cnr+/+ and cnr2-/- strains. In contrast, CBD exposure did have a dose-dependent effect and 
a significant increase in mortality was only seen at the highest concentration of 4 μM 
where mortality was 100% and 90 ± 4.47 % in the cnr+/+ and cnr2-/- strains, respectively 
(Figure 3). 
When control (cnr+/+) larval zebrafish were exposed to THC, LC50 mortality was 
calculated to be 7.2 μM THC (Figure 4A). In contrast, cnr2-/- mutants were more sensitive 











Figure 3: Percent mortality (mean ± SE, n = 5) of 96 hpf larval 
zebrafish developmentally exposed to THC or CBD. An asterisk 
indicates a significant difference compared with the within-strain 




       
 
Figure 4: Strain-dependent probit determined LC50 comparison of fli 
(A) and cnr2-/- (B) both show significantly increased mortality with 











3.2 Role of cnr2 in THC and CBD-induced morphological deficits  
 When cnr+/+ larval zebrafish were exposed to THC and CBD, there was a dose-
dependent decrease in the length of the fish. Specifically, for THC, there was a 
significant decline in length as the concentration increased to 9.5 μM (Figure 6A). 
Similarly, exposure to CBD in the cnr+/+ strain resulted in significant decreased larval 
length starting at 0.5 μM. (Figure 6B). 
Exposure to THC in cnr2-/- mutant zebrafish also resulted in a significant decline 
in length at 4 μM (Figure 6C). When this strain was exposed to CBD, it resulted in a 
downward trend in length as the dose increased with a significant decrease seen at the 
highest concentration of CBD (4 μM) (Figure 6D).  
Similarly, larval eye area decreased as concentration increased for both THC and 
CBD in both strains (Figure 7 A-D). One difference between strains was that the cnr+/+ 
wild-type strain had significantly decreased in eye area starting at 0.5 μM (Figure 7B) 
while cnr2-/- was less affected by CBD exposure as larval eye area did not significantly 






Figure 5: Photos of larval fish taken using a MicroFire® camera using the Picture Frame™ 
Application 2.3 software. Photos were taken of each of the two strains when they were 
developmentally exposed to THC and CBD. The phenotypes were scored by three blind reviewers 







Figure 6: Larval length (mm) of 96 hpf zebrafish that were developmentally 
exposed to THC and CBD. Different letters indicate a significant distance between 
groups (ANOVA, Tukey’s Posthoc, p ≤ 0.05). Red X’s indicate that there was no 
survival at that concentration. A box and whisker plot was used where the box 
represents the interquartile range (IQR), the line within the box represents the 
median, the area of box above the line represents the upper quartile (75th 
percentile), the area of the box below the median line represents the lower quartile 
(25th percentile), and the whiskers represent the remaining quartiles, with any 



















Figure 7: Larval eye area (mm2) of 96 hpf zebrafish that were developmentally 
exposed to THC and CBD. Different letters indicate a significant distance between 
groups (ANOVA, Tukey’s Posthoc, p ≤ 0.05). Red X’s indicate that there was no 





3.3 Role of cnr2 in THC and CBD-induced larval behavioral deficits 
When cnr+/+ and cnr2-/- zebrafish were exposed to THC, larval behavior showed a 
dose-dependent decrease in total movement in both strains during the dark phase. During 
the light phase, this dose-dependent effect was not observed in either strain and in the 
cnr2-/- strain, locomotor activity increased with concentration during the light phase 
(Figure 8). 
Similarly, when cnr+/+ and cnr2-/- zebrafish were exposed to CBD there was a 
dose-dependent decrease in activity during the dark phase. During the light phase, this 
dose-dependent effect was not observed in either strain, and in the cnr+/+ strain, 




Figure 8: Distance travelled (mm) by larval zebrafish that were developmentally exposed to THC. These graphs show the total 
distance travelled during the light and dark phase of 96 hpf larval zebrafish. Different letters indicate a significant distance between 
groups within the light and dark phases (ANOVA, Tukey’s Posthoc, p< 0.05). Red X’s indicate that there was no survival at that 
concentration. 
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Figure 9: Distance travelled (mm) by larval zebrafish that were developmentally exposed to CBD. These graphs show the total 
distance travelled during the light and dark phase of 96 hpf larval zebrafish. Different letters indicate a significant distance between 
groups within the light and dark phases (ANOVA, Tukey’s Posthoc, p< 0.05).  
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3.4 Role of cnr2 in THC and CBD-induced adult behavioral deficits 
 Adult zebrafish were studied in an open-field test and the total distance traveled 
(cm) and percent time spent in the periphery was analyzed. When seven-month-old males 
were examined, there was a significant increase in the total distance traveled by the cnr2-
/- zebrafish when compared to the fli, 5D, and cnr1-/- strains (Figure 10A). The cnr2-/- 
mutant adults also spent significantly more time in the periphery than the cnr1-/- mutant 
strain (Figure 10B). 
When seven-month-old adult females were examined, there was a significant 
increase in the total distance traveled in the cnr2-/- strain when comparing this strain to 
the wildtype fli strain (Figure 11A). The cnr2-/- strain also spent more time in the 








Figure 10: Distance travelled (mm) and time spent in periphery (%) by seven-month 
old male zebrafish of the fli, 5D, cnr1-/-, and cnr2-/- that were not developmentally 
exposed to cannabinoids. Different letters indicate a significant distance between 






 Figure 11: Distance travelled (mm) and time spent in periphery (%) by seven-month 
old female zebrafish of the fli, 5D, cnr1-/-, and cnr2-/- that were not developmentally 
exposed to cannabinoids. Different letters indicate a significant distance between 




            
 
 




4.1 THC and CBD Toxicity  
The effects of THC and CBD are modulated, at least in part, by cannabinoid 
receptors (Cristino et al., 2020). The results of this study further indicated this modulation 
because when the cnr2-/- fish were exposed to THC, they had significantly increased 
mortality at lower concentrations than the cnr+/+ strain. This is consistent with previous 
studies indicating that cannabinoid receptor knockout disrupts metabolic function which 
can contribute to the increased toxicity when the cnr2-/- stain is developmentally exposed 
(Liu et al., 2016).  
When the cnr2-/- strain was exposed to CBD, there was not as significant of an 
effect compared to the cnr+/+ strain which implies that there may be a different 
mechanism of action for each of the cannabinoids. Compared to THC, CBD has a much 
lower affinity for cannabinoid receptors 1 and 2 and studies indicate that CBD may have 
modes of action independent of cnr1 and cnr2 (Pertwee, 2008). 
4.2 THC and CBD Morphological Effects   
A previous study on cnr mutants demonstrated that genetic or chemical inhibition 
of cannabinoid receptor activity disrupts liver development and metabolic function in 
zebrafish (Liu et al., 2016). One specific metabolic pathway that is differentially 
expressed following exposure to CBD or THC is retinol metabolism that has a large role 
in development of the eye as we have hypothesized in our manuscript (Pandelides et al., 




pathway (Tle et al., 2012). The difference in eye sizes seen between THC and CBD 
developmental exposure supports that these morphological deficits could be due to 
disruption of metabolism, specifically retinol. The results of our study suggest that this 
disruption of metabolic function can lead to phenotypic changes such as the decreased 
length, decreased larval locomotor behavior, and anxious adult behavior. Furthermore, 
our laboratory has previously shown that this decrease in size due to developmental THC 
or CBD exposure persists into old age (2.5 years) for female zebrafish (Pandelides et al., 
2020). 
4.3 Larval Behavioral Assessment  
Swimming starts in zebrafish at 48-72 hpf although embryos as early as 27 hpf 
can swim in response to touch if they are dechorionated. When zebrafish reach 96 hpf, 
they create a pattern of increased movement in the dark followed by a resting state in the 
light when exposed to alternating light and dark stimuli (Saint-Amant and Drapeau, 
1998). To evaluate behavior of zebrafish, we use a larval photomotor response assay to 
assess changes in swimming activity following a cyclical light-dark stimulus. The 
rationale for this assay is that, assuming the larvae are not malformed, an abnormal larval 
photomotor response in an otherwise normal animal implicates neurotoxicity (Burgess & 
Granato, 2007). This increased activity under dark conditions is consistent with our 
results as activity was much higher during the 100% dark conditions than the light 
conditions in each strain when exposed to either cannabinoid. This is suggested to be due 
to the evolutionary advantage this affords the zebrafish as the sensitivity to darkness most 
likely evolved to drive them to seek out light conditions in order to be in conditions that 
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better allow them to feed and avoid predators (Burgess & Granato, 2007; Emran et al., 
2008). 
Exposure to THC or CBD generally resulted in a decrease in total distance 
travelled as cannabinoid concentration increased, with the cnr2-/- strain being more 
sensitive to both THC and CBD exposure than the cnr+/+ strain. Previous studies have 
shown that CB1 receptor modulates many of the behavioral effects of THC as cnr1-/- 
strains had a more tolerant response to cannabinoid exposure (Schnörr et al., 2012). The 
results from the cnr2-/- strain suggests that the Cnr2 may have a protective effect against 
cannabinoid exposure mediated by Cnr2’s association with suppressing harmful 
inflammation activity (Colon-Cruz et al., 2020; Y. J. Liu et al., 2013). There was a larger 
difference between cnr+/+ and cnr2-/- when the strains were exposed to CBD than when 
exposed to THC which could be due to the different binding affinity of the cannabinoids 
for the receptors or the fact that studies indicate that CBD may have modes of action 
independent of cnr1 and cnr 2 (Pertwee, 2008)..  
In addition to the Cnr1 and Cnr2, several other endocannabinoid receptors may 
influence the effects of THC and CBD on behavior because the endocannabinoid system 
is not completely understood. One example that fits with our other predictions in this 
study could be that locomotor behavior in zebrafish exposed to THC and CBD is not due 
to the receptor’s activities on behavior directly, but due to the morphological deficits that 
the cannabinoids caused during the developmental exposure such as eye area. Eye 
development could affect behavior because, as mentioned previously, retinol metabolism 
is essential to eye development and may be disrupted by cannabinoid exposure. Without 
proper eye development, the zebrafish would not be able to as adequately respond to the 
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light and dark stimuli. To further add to the understanding of cannabinoid effects on 
larval locomotor activity future studies should use the larval anxiety-like behavior assay 
created by Schnörr by examining larval thigmotaxic behavior (Schnörr et al., 2012). This 
would not only add more to our understanding of the Cnr2 but could also allow for a 
more reliable comparison of larval behavior to adult zebrafish behavior.  
 4.4 Adult Behavioral Assessment   
To examine the effect of cannabinoid receptor presence and loss on behavior in 
unexposed seven-month adult zebrafish, we performed an open-field test specifically 
looking at total movement and thigmotaxis. The open-field test was derived from the 
traditional rodent behavior-based screening method for validation of pharmacological 
effects of neuroactive compounds which in our case are cannabinoids (Prut & Belzung, 
2003). Thigmotaxis is also known as “wall-hugging” or “wall-following” and is an 
anxiety-like behavior that presents itself as the propensity of a fish to avoid the center of 
the arena and stay or move toward the boundary of the environment, or in our case, 
bucket. Thigmotaxis is believed to be an evolutionarily adapted trait to assist animals in 
protection and escape which both occur during stressful situations (Champagne et al., 
2010; Patton et al., 2010), and we examined the role that cannabinoid receptors have in 
this stress-response. Our results for adult male zebrafish showed that males of the cnr2-/- 
strain spent significantly more time in the periphery thus exhibiting more anxious 
behavior when compared to the cnr1-/- strain. The females of the cnr2
-/-
 strain also spent 
significantly more time in the periphery, but it was only significant in comparison to the 
wildtype 5D strain. These results are consistent with other studies that saw Cnr2 
overexpression reducing anxiety-like behaviors (García-Gutiérrez and Manzanares, 
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2011), and thus knocking out this receptor would reduce the positive benefit generated by 
overexpression and result in an increased occurrence of these behaviors. In adult males, 
these results may suggest that Cnr2 plays a larger role in modulating anxiety behaviors 
than Cnr1.  
For total distance traveled, both males and females of the cnr2-/- strain showed a 
significant increase in movement when compared to the fli strain. However, differences 
in significance between sex were observed because not only were males of the cnr2-/- 
strain significantly more active when compared to the fli strain, but also when compared 
to every other strain analyzed in the study. These differences in significance may indicate 
that sex plays a factor in overall locomotor.  
4.5 Conclusion 
This study found that developmental exposure to THC or CBD in zebrafish results 
in significant effects on morphology and larval behavior that was consistent with 
previous studies. Seven-month adult behavior also differed between strains indicating 
cannabinoid receptor involvement in behavior. Overall, these data demonstrate that 
exposure to THC and CBD during development causes significant adverse outcomes. 
However, the effects of exposure to THC and CBD were lessened in zebrafish that lacked 
cannabinoid receptors 2 suggesting that this receptor has an important role in modulating 
the effects of cannabinoid exposure.  
Our study on developmental exposure with different strains shines a bit of light on 
how the use of cannabinoids during development may affect the embryo’s development 
through our evaluated endpoints of morality, larval length, eye area, larval behavior, and 
adult behavior. There is still need for more work to determine if the cannabinoid 
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receptors are truly conferring the results presented in this study. As mentioned 
previously, a logical next step would involve further research into the adverse effects 
caused by metabolic disruption, specifically metabolism of retinol. This would allow for 
a more well-rounded understanding of whether the cannabinoid receptors are directly 
involved in the adverse effects seen in mortality, morphology, and behavior, or if it is a 
consequence of the receptor’s involvement in other processes.  
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